Table of Content

Open Access iconOpen Access

ARTICLE

Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients

Baohong Yang*1, Aiying Qin†1, Kongyuan Zhang, Haipeng Ren*, Shuzhen Liu*, Xiaolei Liu§, Xiangpo Pan, Guohua Yu*

* Department of Oncology, Wei Fang People’s Hospital, Wei Fang, Shandong Province, P.R. China
† The Third Department of Oncology, Luoyang Central Hospital Affiliated with Zhengzhou University, Luoyang, P.R. China
‡ Department of Radiology, Wei Fang People’s Hospital, Wei Fang, Shandong Province, P.R. China
§ Respiratory Department, Weifang Medical University, Wei Fang, Shandong Province, P.R. China
¶ Department of Medical Laboratory, Wei Fang People’s Hospital, Wei Fang, Shandong Province, P.R. China
1 These authors provided equal contribution to this work.

Oncology Research 2017, 25(9), 1601-1606. https://doi.org/10.3727/096504017X14928634401178

Abstract

Epithelial growth factor receptor (EGFR) mutations are present in 10%–26% of non-small cell lung cancer (NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possible role in providing prognostic information. Enrolled patients received erlotinib (150 mg) or gefitinib (250 mg) orally once daily as the first-line treatment. Serial blood samples were taken at baseline (CTC-d0) and on day 28 (CTC-d28) following the initiation of erlotinib/gefitinib for detection of CTCs using the CellSearch system. CTCs ≥2 were found in 47/107 (44%) and CTCs ≥5 in 17/107 (15%). The CTC measurements were dichotomized as favorable (<5 CTCs) and unfavorable (≥5 CTCs) groups. The median progressionfree survival (PFS) interval for patients in the favorable group at baseline was 11.1 months, significantly longer than the median PFS time of 6.8 months achieved by patients in the unfavorable group (p = 0.009). Patients in the favorable group on day 28 exhibited significantly longer PFS compared with patients in the unfavorable group (11.6 vs. 6.3 months; p<0.0001). In univariate analysis, CTC-d0≥5 versus CTC-d0 = 0–4 was significantly associated with poor PFS and time-to-treatment failure (TTF). CTC-d28≥5 versus CTC-d28 = 0–4 was significantly associated with a poor PFS outcome. CTC-d0 and CTC-d28 remained independent poor prognostic markers in the stepwise multivariate analysis. Our study indicates that the CTC count is a prognostic factor for PFS and TTF outcomes in patients with advanced EGFR-mutant NSCLC.

Keywords


Cite This Article

APA Style
Yang, B., Qin, A., Zhang, K., Ren, H., Liu, S. et al. (2017). Circulating tumor cells predict prognosis following tyrosine kinase inhibitor treatment in egfr-mutant non-small cell lung cancer patients. Oncology Research, 25(9), 1601-1606. https://doi.org/10.3727/096504017X14928634401178
Vancouver Style
Yang B, Qin A, Zhang K, Ren H, Liu S, Liu X, et al. Circulating tumor cells predict prognosis following tyrosine kinase inhibitor treatment in egfr-mutant non-small cell lung cancer patients. Oncol Res. 2017;25(9):1601-1606 https://doi.org/10.3727/096504017X14928634401178
IEEE Style
B. Yang et al., "Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients," Oncol. Res., vol. 25, no. 9, pp. 1601-1606. 2017. https://doi.org/10.3727/096504017X14928634401178



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 31

    View

  • 21

    Download

  • 0

    Like

Share Link